DS 8201

Drug Profile

DS 8201

Alternative Names: DS-8201a; DS8201

Latest Information Update: 18 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Daiichi Sankyo Company
  • Class Antineoplastics; Drug conjugates; Immunoconjugates; Monoclonal antibodies
  • Mechanism of Action DNA topoisomerase I inhibitors; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Breast cancer
  • Phase I Gastric cancer; Solid tumours

Most Recent Events

  • 11 Sep 2017 Updated efficacy and adverse events data from a phase I trial in Solid tumours presented at the European Society for Medical Oncology (ESMO-2017)
  • 29 Aug 2017 DS 8201 receives Breakthrough Therapy status for Breast cancer (Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA
  • 28 Aug 2017 Bristol-Myers Squibb and Daiichi Sankyo enter into a clinical trial collaboration to develop DS 8201 in combination with nivolumab for HER2-expressing Breast and Bladder cancers in USA and Europe
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top